HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones
CompanyDeals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication
CompanyDrug

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch
CompanyDrug

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch

Cryofocus GERD System Secures NMPA Approval in China
CompanyMedical Device

Cryofocus GERD System Secures NMPA Approval in China

Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody
CompanyDeals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline
CompanyDeals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic
CompanyDrug

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

Beijing Friendship Hospital Launches Cell and Gene Therapy Center for Liver Diseases
Hospital

Beijing Friendship Hospital Launches Cell and Gene Therapy Center for Liver Diseases

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal
CompanyDeals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones
CompanyDeals

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform
CompanyDeals

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform

Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo
CompanyDrug

Adagene’s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo